Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Asif Ali Sells 1,234 Shares

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Asif Ali sold 1,234 shares of the firm’s stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $25.11, for a total transaction of $30,985.74. Following the completion of the sale, the chief financial officer now owns 37,163 shares of the company’s stock, valued at $933,162.93. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Asif Ali also recently made the following trade(s):

• On Friday, March 1st, Asif Ali sold 14,248 shares of Protagonist Therapeutics stock. The stock was sold at an average price of $32.24, for a total transaction of $459,355.52.

Protagonist Therapeutics Trading Up 1.5 %

Shares of NASDAQ PTGX opened at $25.61 on Friday. The company has a 50-day moving average price of $28.52 and a 200-day moving average price of $22.91. Protagonist Therapeutics, Inc. has a 1 year low of $13.72 and a 1 year high of $33.34.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings data on Tuesday, February 27th. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.39. The business had revenue of $60.00 million for the quarter, compared to analyst estimates of $60.00 million. On average, research analysts anticipate that Protagonist Therapeutics, Inc. will post 1.18 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in PTGX. China Universal Asset Management Co. Ltd. lifted its position in shares of Protagonist Therapeutics by 96.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,473 shares of the company’s stock valued at $25,000 after purchasing an additional 723 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of Protagonist Therapeutics during the second quarter valued at about $76,000. Tower Research Capital LLC TRC lifted its position in shares of Protagonist Therapeutics by 88.1% during the second quarter. Tower Research Capital LLC TRC now owns 3,118 shares of the company’s stock valued at $86,000 after purchasing an additional 1,460 shares in the last quarter. Jane Street Group LLC lifted its position in shares of Protagonist Therapeutics by 273.3% during the third quarter. Jane Street Group LLC now owns 10,289 shares of the company’s stock valued at $87,000 after purchasing an additional 7,533 shares in the last quarter. Finally, Virtus ETF Advisers LLC lifted its position in shares of Protagonist Therapeutics by 29.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 4,457 shares of the company’s stock valued at $102,000 after purchasing an additional 1,017 shares in the last quarter. 98.63% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

PTGX has been the subject of a number of research reports. StockNews.com upgraded shares of Protagonist Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, February 28th. HC Wainwright restated a “buy” rating and issued a $38.00 price target on shares of Protagonist Therapeutics in a report on Wednesday, February 28th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Protagonist Therapeutics from $34.00 to $37.00 and gave the company an “overweight” rating in a report on Wednesday, February 28th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.00.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.